Given the significance of SETD2 as a tumor suppressor and SPOP's role in regulating splicing, targeting this axis may offer new therapeutic opportunities in cancer treatment, particularly in cancers like RCC where both proteins are implicated in tumorigenesis and drug resistance. Here, SPOP is linked to renal cell carcinoma.